A New Drug Tested With Standard Chemo for Lymphoma in the Brain and Spine
Original title: Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to see if the drug is safe.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new drug, Golcadomide, for lymphoma in the brain or spinal cord.
Who this trial is for. This trial is for people with large B-cell lymphoma in the brain or spinal cord. It is for people whose cancer came back or is not responding, and it adds Golcadomide to standard chemotherapy.
Where it stands. This trial has not reported results. It is looking at whether adding Golcadomide to standard chemotherapy is safe and helps. Taking part lasts about 2.5 years.
What this means, and what it doesn't
What it could mean: Someone whose situation fits this study could ask their care team about it. The care team can help weigh whether a trial like this makes sense.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.